Home / Business and Economy / Torrent Pharma Q3 Profit Soars 26% Amidst Strong Revenue Growth
Torrent Pharma Q3 Profit Soars 26% Amidst Strong Revenue Growth
13 Feb
Summary
- Net profit rose to ₹635 crore, a 26.3% increase from the previous year.
- Revenue climbed 17.6% to ₹3,303 crore, with strong performance in India.
- An interim dividend of ₹29 per equity share was announced for shareholders.
Torrent Pharmaceuticals Ltd announced a net profit of ₹635 crore for the third quarter of fiscal year 2026, representing a 26.3% increase compared to the same period last year. The company's revenue grew by 17.6% to ₹3,303 crore, with EBITDA rising 19% to ₹1,088 crore.
In its domestic market, India, revenue reached ₹1,798 crore, up 14% year-on-year, outperforming the Indian Pharmaceutical Market's 10% growth. Torrent Pharma's performance in India was notably strong in chronic and sub-chronic therapies, particularly in the cardiac, gastro, and diabetes segments.
The company also experienced significant international growth. Brazil contributed ₹371 crore in revenue, a 27% increase year-on-year, driven by top brands and new launches. The United States business posted revenues of ₹321 crore, up 19% from the prior year, with recent product launches achieving their target market shares.
Germany's revenue saw an 8% growth to ₹304 crore, though this was affected by supply disruptions. Torrent Pharma also declared an interim dividend of ₹29 per equity share, expected to be dispatched around March 6, 2026.
